Prolonged lymphocytosis during ibrutinib therapy is associated with distinct molecular characteristics and does not indicate a suboptimal response to therapy. [Blood. 2014]
Lymphocytosis and ibrutinib treatment of CLL.
ROSSI, Davide;GAIDANO, Gianluca
2014-01-01
Abstract
Prolonged lymphocytosis during ibrutinib therapy is associated with distinct molecular characteristics and does not indicate a suboptimal response to therapy. [Blood. 2014]File in questo prodotto:
File | Dimensione | Formato | |
---|---|---|---|
Lymphocytosis and ibrutinib treatment of CLL..pdf
file disponibile solo agli amministratori
Tipologia:
Documento in Post-print
Licenza:
DRM non definito
Dimensione
583.41 kB
Formato
Adobe PDF
|
583.41 kB | Adobe PDF | Visualizza/Apri Richiedi una copia |
I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.